Cipla secures CDSCO approval for Afrezza, a rapid-acting insulin delivered through an inhaler, offering a convenient solution for diabetes management in India. The drug is the first and only ...

Rhinitis and pharmacological agents used for treatment are considered factors that could alter the rate and extent of absorption of drugs administered by the nasal route. The purpose of this study ...

Qnovia’s nicotine replacement therapy device. [Image courtesy of Qnovia] Qnovia announced that it raised $16 million in Series B funding to support its inhaled smoking cessation therapy platform. Blue ...

a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of a new patient access program, in partnership with Direct Relief, to supply inhalers to ...

Long-term exposure to high levels of air pollution can accelerate the progression of both chronic respiratory diseases and pulmonary hypertension.

The interest in inhalation delivery has continued to rise and was not hindered by the withdrawal of the first inhaled insulin, Exubera, in 2007. In fact over the past four years, 1,350 active ...

Physiologic alterations in CHF, such as changes in absorption, distribution, metabolism, and elimination of drugs, can indeed alter loop diuretic pharmacokinetics; however, these effects do not ...

Afrezza is a rapid-acting insulin delivered through an inhaler compared to current insulins which are given as injections. Taken at the beginning of a meal, the medication dissolves rapidly upon oral ...